Dragana Milojković - Concepedia

Author

Dragana Milojković

Also Known As

Claire Harrison, D Milojkovic, D Milojković, D. Milojkovic, Dong-Wook Kim, Dragana Milojkovic, Dragana Milojković, Dragana Milojković, Kari S Peggs, Milojkovic, D

294

Publications

10.4K

Citations

H-Index

Concepts

All Affiliations

Imperial College London Hammersmith Hospital Imperial College Healthcare NHS Trust University of Liverpool Royal Liverpool University Hospital

About

Dragana Milojković is an author at Imperial College London specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	1.7K
2	Cell Biology	8	8	565
3	Health Sciences	5	5	279
4	Blood Transplantation	3	3	74
5	Engineering	2	2	62

Dragana Milojković

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib David Marín, Alexandra Bazeos, François-Xavier Mahon, Journal of Clinical Oncology	2010	890
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society Alexander R. Lyon, Susan Dent, Susannah Stanway, European Journal of Heart Failure	2020	717
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad, Journal of Clinical Oncology	2008	555
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Journal of Clinical Oncology	2017	480
Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors David Marín, Amr R. Ibrahim, Claire Lucas, Journal of Clinical Oncology	2011	474
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor David Marín, Dragana Milojković, Eduardo Olavarría, Blood	2008	328
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Blood	2011	314
Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome Raj Patel, Nicholas Lea, Michael A. Heneghan, Gastroenterology Budd–chiari SyndromeGenetic DisorderGeneticsPathogenesisPathology	2006	278
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia Dragana Milojković, Jane F. Apperley Clinical Cancer Research Mixed-phenotype Acute LeukemiaImmunologyPharmacotherapyTumor BiologyMyeloid Neoplasia	2009	259
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells Paolo Neviani, Jason G. Harb, Joshua J. Oaks, Journal of Clinical Investigation	2013	215

Page 1